Quantcast

Latest Antibody Stories

Two Separate Studies On MERS-Coronavirus Offer Better Understanding Of Newly Emerging Disease
2014-04-29 09:33:16

Lawrence LeBlond for redOrbit.com - Your Universe Online Two separate studies this week are helping scientists gain a better understanding of the dangerous Middle East respiratory syndrome (MERS) coronavirus, a disease that has sickened more than 300 people and left at least a hundred dead since it was first reported in September 2012. HUMAN ANTIBODIES The first study comes from scientists at Dana-Farber Cancer Institute who have identified natural human antibodies against the virus...

2014-04-28 08:32:25

Extension of trade name reflects growth in customized primary cell biology contract research business SEATTLE, April 28, 2014 /PRNewswire/ -- ReachBio LLC announced today that it is extending its trade name and will start doing business as ReachBio Research Labs, effective immediately. As part of this rebranding, the company has updated its logo and launched a new re-designed website at www.reachbio.com. Photo - http://photos.prnewswire.com/prnh/20140425/78771 According to Rob...

2014-04-23 16:23:51

DUBLIN, April 23, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/cqslzn/chromatography) has announced the addition of the "Chromatography Resin Market by Application, Techniques & Type - Trends & Forecast to 2018" [http://www.researchandmarkets.com/research/cqslzn/chromatography ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Ever increasing application in monoclonal...

2014-04-11 08:24:18

LONDON, April 11, 2014 /PRNewswire/ -- ThioBridge(TM) linker to attach different payloads to a range of antibodies PolyTherics Limited ("PolyTherics"), a provider of technologies and services to enable the development of better biopharmaceuticals, today announced an extension to its ThioBridge(TM) antibody drug conjugate ("ADC") collaboration with MacroGenics Inc (NASDAQ: MGNX), a US biotechnology company developing innovative medicines utilizing its next...

2014-04-10 23:03:15

The findings from The Scripps Research Institute may lead to new insights into immune deficiency, stroke and diabetes. La Jolla, California (PRWEB) April 10, 2014 A team led by scientists at The Scripps Research Institute (TSRI) has identified a long-sought protein that facilitates one of the most basic functions of cells: regulating their volume to keep from swelling excessively. The identification of the protein, dubbed SWELL1, solves a decades-long mystery of cell biology and points to...

2014-04-10 08:29:30

MONROVIA, Calif., April 10, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that the company has received a milestone payment from Merck, through a subsidiary, triggered by the initiation of a Phase 1 clinical trial for an undisclosed biologic drug candidate that uses Xencor's XmAb® antibody...

2014-04-10 08:28:53

NEW YORK, April 10, 2014 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM), is an emerging biopharmaceutical company focused on the $54 billion market for cancer drugs. The Company's most advanced products are Actimab(TM)-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia (AML) and Iomab(TM)-B, an antibody-drug construct containing iodine 131 (I-131), used in myeloconditioning for hematopoietic...

2014-04-07 04:21:25

BREDA, The Netherlands and GHENT, Belgium, April 7, 2014 /PRNewswire/ -- New findings to be presented at the American Association for Cancer Research annual meeting arGEN-X, a clinical stage human therapeutic antibody company, will present data on how its SIMPLE Antibody(TM) platform has identified four 'hotspots' on the MET protein that are suitable for therapeutic antibody targeting. Encoded by the oncogene c-Met, MET...

2014-04-03 16:23:53

AUSTIN, Texas, April 3, 2014 /PRNewswire/ -- XBiotech announced today that it acquired the patent estate of Strox Biopharmaceuticals relating to antibody therapies for methicillin resistant staphylococcus aureus (MRSA). XBiotech is developing next generation natural immune therapies to address serious and drug resistant bacterial infections. The in-licensed technology is reportedly intended to expand and strengthen XBiotech's position for its infectious disease product development...

2014-04-03 12:28:49

TUCSON, Ariz., April 3, 2014 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announced that it has entered into an agreement with Genmab A/S, Copenhagen, Denmark for the development of companion diagnostic tools for Genmab's HuMax-TF®-ADC antibody drug conjugate (ADC) program. As part of the agreement, Ventana will provide its expertise and services towards the development of an immunohistochemistry (IHC) companion diagnostic test for the...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related